Crossmark

Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation

Crossref DOI link: https://doi.org/10.1186/S12931-014-0105-2

Published: 2014-12

Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY

Authors

Ohar, Jill A

Crater, Glenn D

Emmett, Amanda

Ferro, Thomas J

Morris, Andrea N

Raphiou, Ibrahim

Sriram, Peruvemba S

Dransfield, Mark T
License Information

unspecified valid from 2014-09-24
More Information

Article History

Received: 14 April 2014

Accepted: 12 August 2014

First Online: 24 September 2014